Abiopharma

🔍 Hyman Jonathan (Executive)

Company: Braze, Inc. (BRZE)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Sold 15,784 shares of Class A Common Stock at $28.93 per share (Direct)
  Date: 2026-08-17 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,204,632.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 350,000.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 221,436.00 | Footnotes: F4
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 28,564.00 | Footnotes: F4

Footnotes:

• F1: Represents shares withheld to satisfy the reporting person's tax withholding obligations upon vesting and settlement of the underlying equity awards.
• F2: Of the reported shares, 225,596 shares are represented by restricted stock units and performance-based restricted stock units.
• F3: The securities are held by a personal trust. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares.
• F4: The securities are held by a family trust. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares.